Fenofibrate

When ATH:
C10AB05

Pharmacological action.
Hypolipidemic, urikozuricheskoe, antiagregatine.

Application.

Гиперлипидемия типа IIa, Type IV and V, and IIb and III with insufficient the effectiveness of diets, high blood cholesterol in dynamic research and / or the presence of concomitant risk factors (CHD, GB and their complications).

Contraindications.

Hypersensitivity.

Restrictions apply.

Abnormal liver function, including biliary cirrhosis, kalkuleznыy cholecystitis, severe renal insufficiency, alcoholism, pregnancy, lactation.

Pregnancy and breast-feeding.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Side effects.

Cholelithiasis, transaminase elevation and creatine kinase, nausea, vomiting, diarrhea, myalgia, myositis, raʙdomioliz, acute renal failure, dizziness, headache, fatigue, impotence, skin rashes.

Cooperation.

Activity Increases indirect anticoagulants. Enhances hepatotoxicity perhexiline and MAO inhibitors. Lipid-lowering effect of oral contraceptives reduce.

Dosing and Administration.

Inside - By 100 mg 3 once a day, микронизированные формы — по 200 mg 1 once a day.

Precautions.

It is necessary to monitor the activity of transaminases; with an increase in ALT 2 or more times, appearance myalgia and muscle weakness fenofibrate cancel. Treatment should be carried out for a long time, in conjunction with diet and hypolipidemic under medical supervision.

Cooperation